Pathogenesis-based pre-exposure prophylaxis associated with low risk of SARS-CoV-2 infection in healthcare workers at a designated Covid-19 hospital

INTRODUCTION

Covid-19, the novel infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in humans in December 2019 (Zhu et al 2020). As of September 20, 2020, more than 30 million confirmed cases and 950 thousand deaths have been reported worldwide (WHO 2020 - ref.2). The clinical hallmarks of the disease vary from asymptomatic infection to pneumonias featuring ground-glass opacities that might progress to life-threatening complications such as acute respiratory distress syndrome (ARDS) and multisystem organ failure (Guan et al 2020). Older patients and those with preexisting respiratory, cardiovascular and metabolic conditions appear to be at the greatest risk for severe complications and death (Wu et al 2020). A notable genomic feature of SARS-CoV-2 is its long spike (S) glycoprotein, with which has an approximately 80% overlapping sequence identity with those of previous SARS-CoV and MERS viruses (Lu et al 2020). Based on the similarities and past studies of SARS-CoVs, the pathogenesis of Covid-19 likely includes phases of SARS-CoV-2 infection that correspond to viral entry, replication in the upper airway and migration down the respiratory tract, with a robust immune response that triggers hypoxia and progression to ARDS (Cao & Li 2020). In the absence of a proven effective therapy, off-label or compassionate-use compounds have been used to treat Covid-19 with the assumption that airway epithelium damage, a diverse immune response and inflammation predominate in SARS-CoV-2 pathogenicity (Baden & Rubin 2020). Though there are currently more than one hundred Covid-19 candidate vaccines in development (WHO 2020 - ref.8), to date, no agents are known to be effective in preventing SARS-CoV-2 infection (NIH 2020).

Angiotensin-converting enzyme 2 (ACE2) has been identified to act as a receptor and an entry point for SARS-CoV-2, similar to what has been previously identified with SARS-CoVs (Hoffmann et al 2020). However, structural, biochemical and modeling data have revealed that SARS-CoV-2 might recognize ACE2 with a binding affinity that is an order of a magnitude greater than that for SARS-CoV (Shang et al 2020, Wrapp et al 2020). Marked ACE2 expression was found in the nose and alveolar epithelial cells, and presented in arterial smooth muscle cells and endothelial cells (Hamming et al 2004, Hou et al 2020), although there were found generally low ACE2 expression in cells from airways (Sungnak et al 2020). ACE2 represses the production of angiotensin II (Ang II) by angiotensin-converting enzyme (Donoghue et al 2000). Previous studies have reported considerably reduced ACE2 expression in the lungs of wild-type mice infected with SARS-CoV, suggesting that ACE2 might have a role in SARS-CoV-mediated severe acute lung pathologies (Kuba et al 2005). When SARS-CoVs interact with ACE2 to gain entry into cells, the downregulation of ACE2 – either directly due to viral binding or indirectly due to cell lysis – decreases Ang II inhibition (Rivellese & Prediletto 2020). Therefore, SARS-CoV-2 can reduce ACE2 activity and receptor consumption, further exacerbating an ACE2/Ang II regulatory imbalance (Cheng et al 2020), resulting in hypoxic pulmonary vasoconstriction (HPV) and impaired metabolic homeostasis in smooth muscle cells (SMCs) of distal bronchiolar airways.

Taken together, the key role of ACE2 in SARS-CoV-2 infection, the exceeding viral binding affinity of SARS-CoV-2 to the ACE2 receptor, and the documented severity of Covid-19 in subjects with respiratory, cardiovascular and metabolic conditions led us to hypothesize that the HPV and impaired airway SMC metabolic homeostasis, resulting from the robust SARS-CoV-2 virus-induced ACE2/Ang II regulatory imbalance, might prevail over the diverse immune response at the initial phase of Covid-19 pathogenesis. Though HPV is a physiological mechanism by which pulmonary arteries maintain blood oxygenation during alveolar hypoxia (Sylvester et al 2012), Ang II can induce robust pulmonary vasoconstriction via angiotensin receptor 1 (AT1R) (Forrester et al 2018), and causes internalization and degradation of membrane Ca2+-activated K+ channels (BKCa), providing an additional mechanism to contribute to vasoconstriction (Leo et al 2015). In addition, hypoxia, per se, might act either directly on peripheral pulmonary arterial SMCs either to inhibit a voltage-sensitive K⁺ channel (Kv) and induce membrane depolarization, and contraction (Patel et al 1997) or indirectly to stimulate release of vasoconstrictors and/or inhibit release of vasodilators (Sato et al 2000). Genome-wide transcriptome analyses in vivo after Ang II infusion have revealed upregulated genes in metabolism and ion transport pathways, while genes protective against oxidative stress, including glutathione synthetase and mitochondrial superoxide dismutase 2, were downregulated (Makhanova et al 2010). The disruption of reduction-oxidation (redox) signaling and excessive generation of reactive oxygen species by the injured pulmonary endothelium/epithelium under pathological conditions leads to increased endothelial permeability and upregulated expression of proinflammatory cytokines and adhesion molecules, amplifying tissue damage and pulmonary edema (Kellner et al 2017) Therefore, we hypothesized that SARS-CoV-2 infectivity and pathogenicity, and the resulting pulmonary abnormalities induced by an ACE2/Ang II regulatory imbalance, might be attenuated by directly maintaining the innate redox, dilation and metabolic functions of the lung using appropriate and well-tolerated medications.

There are currently available safe medications that have been previously reported to maintain ventilation-perfusion functions of the lung. A prime example is glutathione (γ-L-glutamyl-L-cysteinyl-glycine, GSH), a main nonprotein thiol (Meister & Anderson 1983), that decreases in alveolar epithelial cells upon exposure to toxins or respiratory viruses (Mulier et al 1998), and this decrease is associated with increased superoxide production and proinflammatory cytokine release (Papi et al 2008). It has been reported that GSH can be delivered by aerosol to directly augment the GSH level in the epithelial lining fluid of the lower respiratory tract in vivo (Buhl et al 1990) and to improve clinical outcome in patients with cystic fibrosis (Bishop et al 2005). GSH treatment of isolated bronchi in vitro resulted in decreases in SMCs contraction and bronchodilation (Casoni et al 2003), which increases membrane hyperpolarization via potassium (K+) channels on airway SMCs (Deshpande et al 2010). In the human lung, Kv and BKCa channels located in the apical membrane contribute to high K+ content in adult airway surface liquid (Valeyre et al 1991), and extracellular K+ is involved in matching tissue blood flow as a mediator of functional vasodilation (Haddy et al 2006). Moreover, vasodilators that act through receptors coupled to guanine nucleotide binding protein (G-protein) activate K+ channels through the cAMP signaling cascade, which includes adenosine (Kleppisch & Nelson 1995). The hydrolytic deamination of adenosine generates inosine, which increases in the extracellular space under metabolically stressful conditions and has been shown to have powerful immunomodulatory and cytoprotective activity by binding to G-protein-coupled A2A adenosine receptors (Hasko et al 2008). Inosine might serve as an alternative substrate for ATP generation during hypoxia (Módis et al 2009) and protects the bronchial and alveolar epithelium from the potentially deleterious consequences of neutrophil accumulation (Qiu et al 2000). Inosine might also exert antiviral effects through the incorporation into double-stranded viral RNA and potentiation of immune system sensing (Sarvestani et al 2014). It is important to note here that inosine-based compounds are amongst the drugs that being re-purposed for management of Covid-19 (Kumar et al 2020), and the efficacy of high-dose glutathione therapy in relieving dyspnea associated with Covid-19 pneumonia has been recently reported (Horowitz et al 2020).

Healthcare workers (HCWs) are at particularly high risk of acquiring SARS-CoV-2, from repeated exposure to infected patients (Hunter et al 2020, Suárez-García et al 2020). Based on the high risk of the infection in this population, the rationale presented above and the absence of effective agents to prevent or treat Covid-19, we aimed to evaluate whether pre-exposure prophylaxis (PrEP) using a low-dose aerosolized combination of glutathione, inosine and potassium might prevent SARS-CoV-2 acquisition in healthy adults who are at high risk for exposure to this infection.

MATERIAL AND METHODS

Study procedures

From the full staff of HCWs at the hospital, 99 volunteers were assigned to a study condition among 100 HCWs who were randomly recruited to participate in the study by members of the study team at the hospital from June 1 to June 12, 2020 (Figure 1). All participants completed a pre-enrollment evaluation, which included data from genetic and serology SARS-CoV-2 tests performed prior to enrollment. Data on treatment adherence and adverse events were collected on day 7 and day 14; additional follow-up information was solicited through day 28. The primary outcome was new-onset SARS-CoV-2 infection, detected by genetic or immunological tests over the study period. A comparison group of HCWs from the hospital was analyzed retrospectively among HCWs who were not included in the study group, were virus- and sera-negative at the end of May, 2020 and either worked until the final date of the study. All HCWs in the hospital were tested for SARS-CoV-2 weekly in accordance with national guidelines and recommendations. Additionally, all HCWs received qualitative serological testing for IgM and IgG against SARS-CoV-2 at the end of May and beginning of July, 2020. Therefore, outcome data in the comparison group were collected from the results of these routine tests.

• Download figure
• Open in new tab

Figure 1. Flow diagram showing the progress of healthy subjects throughout the study.

RESULTS

During the study period (June 1, 2020, to July 10, 2020), the cumulative number of patients with Covid-19 in the hospital increased from 447 to 884 (97.8%). Among the 410 HCWs who worked at the hospital, 43 (10.5%) were SARS-CoV-2 positive before the beginning of the study (n=29), or did not work until the final date of the study (n=14); 99 HCWs were enrolled as participants in the study (24.1%); the remaining 268 HCWs were designated as the comparison group (65.4%).

The mean age of the participants was 27.0 years (95% CI: 25.3 to 28.7), 69% were female, and 52% were nurses (51/99). The demographic characteristics of the participants and the comparison group did not differ significantly (Table 1).

During the study period, no serious adverse events were observed in the ACM group, and none of the prespecified stopping rules were met. During the treatment period, solicited systemic and common adverse events, which occurred in five participants (5%), included headache in two participants (2%), itchy throat in two participants (2%) and dry cough in one participant (1%); all were mild and transient reactions lasting no longer than 30 min during or after the inhalation session. The adverse events revealed no patterns of concern; neither treatment interruption nor modification was indicated.

The total incidence of SARS-CoV-2 detected in the ACM group was 2% (2/99; 95% CI: 0.3% to 7.1%), which was significantly less than the virus- or sera-positivity rate in the comparison group, which was 9% (24/268; 95% CI: 5.8% to 13.0%; P = 0.02) (Figure 2).

• Download figure
• Open in new tab

Figure 2. Cumulative SARS-CoV-2 incidence in HCWs*.

*HCWs – healthcare workers. ACM – aerosoled combination medication. PrEP – pre-exposure prophylaxis with ACM.

DISCUSSION

Here, we report that the pathogenesis-based prophylaxis associated with significant reduction of SARS-CoV-2 incidence to 2% in HCWs who delivered care and services to patients with Covid-19 compared with 9% incidence in remaining HCWs who did not use the treatment at the same hospital during the entire study period. Effective PrEP for Covid-19 would not only safely prevent high-risk individuals from acquiring SARS-CoV-2 infection from close contacts infected with the virus but also could attenuate the infection if it did occur. At present, most clinical trials of pharmacologic interventions to prevent SARS-CoV-2 infection have been conducted with medications that were previously used in the treatment of Covid-19 (e.g., hydroxychloroquine), and have focused on evaluating the safety of these drugs in this new context (Cohen 2020). To date, this repurposing of established drugs and the development of vaccines has been mainly driven by the common approach of considering SARS-CoV-2 virulence and the host immune reaction as the primary factors in the pathogenesis of Covid-19 (Cao & Li 2020). In contrast, based on the triggering role of an ACE2/Ang II imbalance in SARS-CoV-2 pathogenicity (Cheng et al 2020, Rivellese & Prediletto 2020), we hypothesized that Covid-19 might be attenuated by direct maintenance of innate pulmonary redox, dilation and metabolic functions using a combination of medications that were previously reported to be well tolerated after aerosol delivery to human airways. Using an aerosolized combination of glutathione, potassium and inosine at low doses, we designed and conducted a low-intervention prospective open-label study of PrEP in healthy participants at high risk of acquiring SARS-CoV-2 due to their repeated exposure to confirmed Covid-19 patients. Here we have shown the safety and efficacy of the pathogenesis-based PrEP for SARS-CoV-2 infection, and also highlight the following aspects in address of Covid-19 prevention and treatment.

In the study, ACM had no serious adverse events at the chosen dose of 21.3 mg ml/1 glutathione and 8.7 mg ml/1 inosine in hypo-osmolar potassium chloride solution. This is consistent with previous data that showed good tolerance of the inhaled components of ACM separately at doses up to an order of magnitude greater in healthy participants or patients. In particular, no toxic or adverse effects were observed for inhaled glutathione at doses of 300 mg or more when administered to participants with pulmonary fibrosis (Griese et al 2004). Inosine solution, when inhaled at concentrations up to 373 µmol (100 mg)/ml, had no effect on airway responses in healthy and asthmatic participants (Mann et al 1986). Therefore, a combination of these medications at low doses, used simultaneously, might be an optimal way to attenuate the main steps of Covid-19 pathogenesis. Importantly, some of the agents can exert a number of physiological effects, increasing the cumulative antiviral efficiency of the combined medication. For instance, in addition to the metabolic activity of inosine, adenosine to inosine modification (A- to-I) by adenosine deaminases acting on RNA is a recently discovered process of posttranscriptional pre-mRNA modification (Nishikura 2016). This process exerts antiviral effects through the incorporation of inosine into double-stranded viral RNA followed by RNase-specific viral degradation (Scadden & Smith 1997) and through potentiation of immune system sensing (Sarvestani et al 2014).

The significant reduction of SARS-CoV-2 incidence among HCWs treated with ACM in our study might support the hypothesized importance of the virus-induced ACE2/Ang II regulatory imbalance in human airways, along with the consequent robust pulmonary hypoxia and peripheral ventilation-perfusion abnormalities. Moreover, these results suggest the important prevalence of these processes over the diverse host immune response and viral load, per se, in the pathogenesis of Covid-19. Our approach and findings might be used either to prevent SARS-CoV-2 infection or, even more effectively, to support ongoing and new research into more effective treatments for Covid-19. Further studies of pathogenesis-based combination medications for the prophylaxis and treatment of this severe disease need to be performed in greater detail using multi-centre randomized placebo-controlled methods.